Atropine And Diphenoxylate

Introduction Overview

Generic Name

atropine and diphenoxylate

Brand Name

Lomotil

Dosage Form

Tablet; Oral solution

Drug Class

Antidiarrheals

Pharmacokinetics

Absorption:
Diphenoxylate, a synthetic opioid, is rapidly and extensively absorbed from the gastrointestinal tract following oral administration. Atropine, administered concomitantly in subtherapeutic doses, is also absorbed through the digestive system but primarily functions to discourage diphenoxylate abuse rather than exert significant pharmacologic effects at these low doses. The onset of action for diphenoxylate is typically within 45 to 60 minutes post-dose, facilitating prompt antidiarrheal effects. Food intake does not significantly affect the absorption of diphenoxylate, allowing administration with or without meals. However, the anticholinergic effects of atropine may cause some variability in gastrointestinal motility that warrants monitoring.

Distribution:
Diphenoxylate exhibits moderate binding to plasma proteins, approximately 50%, facilitating distribution throughout the systemic circulation and across the intestinal smooth muscle tissues where its therapeutic effect is exerted. The volume of distribution is moderate, signifying penetration into peripheral tissues. Atropine, being a tertiary amine, readily crosses lipid membranes and distributes broadly in body tissues, including crossing the blood-brain barrier, contributing to its central and peripheral anticholinergic effects. The combined distribution profiles support the synergistic action on gastrointestinal motility.

Metabolism:
Diphenoxylate undergoes hepatic metabolism primarily through hydrolysis and demethylation pathways catalyzed by liver enzymes such as cytochrome P450 isoforms, generating active and inactive metabolites, including diphenoxylic acid, which retains some antidiarrheal activity but with lesser potency. Atropine is metabolized hepatic ally via hydrolysis and demethylation, generating a variety of metabolites excreted in urine and bile. The metabolic clearance of both components can be influenced by hepatic function, and caution is advised in patients with liver impairment due to altered drug elimination and increased potential for toxicity.

Elimination:
The elimination of diphenoxylate and its metabolites occurs predominantly through renal excretion, with approximately 90% of the drug and metabolites eliminated via the kidneys. The elimination half-life of diphenoxylate is approximately 12 to 14 hours, supporting dosing intervals of every 6 to 8 hours. Atropine elimination similarly depends on renal excretion, with a half-life of 2 to 4 hours; however, the small dose in Lomotil minimizes systemic accumulation. Renal impairment may prolong elimination and enhance the risk of side effects. Clinical monitoring of renal function is recommended for long-term use or in patients with compromised renal clearance.

Dosage Forms

Available Dosage Forms:
Lomotil is available as oral tablets and oral solutions designed for accurate dosing in adults and adolescents. The tablet form contains fixed doses of diphenoxylate hydrochloride 2.5 mg combined with atropine sulfate 0.025 mg per tablet. The oral solution formulation typically contains 2.5 mg diphenoxylate per 5 mL with 0.025 mg atropine per 5 mL, allowing flexible dosing in patients who may require liquid administration.

Dosages for Adults and Adolescents:
The recommended dosage for patients aged 13 years and older is one to two tablets or 5 mL of the oral solution administered up to four times daily, after each loose stool. Maximum daily dose should not exceed 20 mg of diphenoxylate to reduce the risk of central nervous system and anticholinergic toxicity. Therapy duration should be limited to short courses, typically no longer than 10 days, to avoid masking serious underlying diseases.

Specific Patient Populations:
Lomotil is not approved for use in children under 6 years of age and has limited evidence supporting safety and efficacy in children aged 6 to 13 years; thus, use in pediatric populations younger than 13 is generally discouraged. In elderly patients or those with hepatic or renal impairment, starting with lower doses and careful titration is recommended due to altered drug metabolism and clearance. Pregnant and breastfeeding women should only use this medication if clearly needed, following risk-benefit assessment by the healthcare provider.

Mechanism Of Action

Lomotil combines diphenoxylate, an opioid receptor agonist, with atropine, an anticholinergic agent, to synergistically reduce diarrhea symptoms primarily by decreasing intestinal motility. Diphenoxylate acts predominantly on the smooth muscle of the gastrointestinal tract by binding to mu-opioid receptors, which leads to the inhibition of peristalsis. This binding reduces the transit rate of intestinal contents, allowing increased absorption of electrolytes and water, resulting in firmer stools and decreased frequency of defecation.

At a cellular level, diphenoxylate reduces cyclic adenosine monophosphate (cAMP) levels through opioid receptor activation, which diminishes calcium influx and neurotransmitter release in enteric neurons, attenuating motility and secretory reflexes. Unlike other opioids, diphenoxylate is formulated with limited central nervous system penetration, minimizing analgesic and euphoric effects while maximizing peripheral antidiarrheal action.

Atropine, included in subtherapeutic doses, exerts its mechanism by competitively inhibiting muscarinic acetylcholine receptors on the parasympathetic nerves in the gastrointestinal tract. This inhibition further decreases the secretory activity and smooth muscle spasms mediated by cholinergic pathways. Although the atropine dose is low to primarily discourage diphenoxylate overuse by producing unpleasant anticholinergic side effects at higher doses, it modestly enhances the antidiarrheal profile of diphenoxylate.

Clinical studies demonstrate that the combination effectively reduces stool frequency, improves stool consistency, and alleviates abdominal cramps without producing tolerance or dependency at therapeutic dosages. Compared to loperamide, another opioid antidiarrheal, Lomotil has a different regulatory status, with more potential for central effects due to diphenoxylate's opioid class, justifying the presence of atropine to mitigate misuse risks.

Pharmacological Actions

Acts as an antidiarrheal by decreasing intestinal motility via opioid receptor agonism.
Reduces water and electrolyte secretion into the intestinal lumen.
Atropine component inhibits parasympathetic stimulation reducing gastrointestinal secretions and spasms.
Controls symptoms of acute and chronic diarrhea.
Modulates enteric nervous system activity to restore normal bowel function.
Exhibits minimal central opioid effects at therapeutic doses due to low CNS penetration.
Prevents fluid loss and dehydration associated with frequent watery stools.
Anticholinergic effects of atropine discourage diphenoxylate abuse.
Slows peristaltic movements allowing greater absorption of fluids and electrolytes.
Reduces abdominal cramping by relaxing smooth muscle in intestines.
Useful in managing non-infectious diarrhea where decreased motility is desired.
May have mild analgesic effects secondary to opioid receptor activation.
Demonstrates synergistic effect of opioid and anticholinergic components for enhanced efficacy.

Therapeutic Or Clinical Uses

Management of acute nonspecific diarrhea in adults and children aged 13 years and above.
Treatment of chronic diarrhea where slowing of intestinal transit is beneficial.
Adjunct therapy for symptomatic relief in irritable bowel syndrome with diarrhea.
Reduction of stool frequency and volume in patients with inflammatory bowel disorders.
Control of diarrhea in travelers experiencing acute infectious diarrhea symptoms after infectious causes have been ruled out.
Use in hospitalized patients to reduce fecal output for hygiene and skin protection.
Maintenance therapy in patients with short bowel syndrome or malabsorption syndromes under supervision.
Symptomatic treatment of diarrhea induced by medications or medical conditions causing hypermotility.
Reduction of diarrhea-related dehydration when combined with oral rehydration therapy.
Off-label use for management of colostomy patients to reduce stoma output.

Side Or Adverse Effects

Drowsiness and dizziness, affecting the ability to perform tasks requiring alertness.
Dry mouth, nose, and throat due to anticholinergic effects of atropine.
Headache and feeling restless or nervous.
Nausea, vomiting, and upset stomach in some patients.
Confusion, hallucinations, or excitement especially in elderly or overdose situations.
Severe constipation and abdominal bloating or pain indicating potential toxicity.
Rapid or weak heartbeat and palpitations linked to atropine's cardiac effects.
Flushing or warmth sensation due to atropine-mediated vasodilation.
Numbness or tingling sensations in hands or feet reported rarely.
Depression or mood alterations as CNS adverse effects at higher doses.
Skin rash, dryness, or itching related to hypersensitivity reactions.
Respiratory depression or shallow breathing in overdose scenarios.
Visual disturbances such as blurred vision due to anticholinergic effects.
Potential for dependence or abuse with prolonged or high-dose use.
Risk of serious allergic reactions, including swelling of face or throat (anaphylaxis).

Precautions

Use with caution in patients with glaucoma due to atropine-induced increased intraocular pressure.
Avoid in patients with obstructive jaundice or bile duct disorders.
Monitor bowel function to avoid severe constipation and toxic megacolon, especially in ulcerative colitis.
Not recommended for use in children under 13 years old due to safety concerns and lack of established efficacy.
Avoid use in patients with respiratory insufficiency or asthma as diphenoxylate may depress respiratory center.
Use cautiously in patients with liver or kidney impairment due to altered metabolism and elimination.
Patients with urinary retention or prostatic hypertrophy should be monitored closely as atropine may exacerbate these conditions.
Be cautious in patients with a history of drug abuse or opioid sensitivity.
Avoid concomitant use with other CNS depressants without medical advice.
Limit use duration to prevent potential dependency or masking of underlying disease.
Ensure adequate hydration and electrolyte balance during treatment with Lomotil.
Pregnant or breastfeeding women should use only if clearly indicated after risk assessment.
Avoid alcohol consumption during treatment to reduce additive CNS effects.
Discontinue medication and seek medical advice if severe abdominal pain or bloody diarrhea occurs.
Healthcare providers should assess for infectious diarrhea before prescribing to avoid delaying treatment of pathogens.

Warnings

Do not use in diarrhea caused by bacterial infections or antibiotic-associated diarrhea.
Contraindicated in obstructive jaundice due to risk of worsening liver function.
Risk of fatal overdose in children; keep medicine out of reach of children.
Use may cause serious side effects including respiratory depression, seizures, or coma in overdose.
Potential for CNS depression and impaired ability to drive or operate machinery.
Avoid if allergic to diphenoxylate, atropine, or any component of the formulation.
May cause severe constipation leading to bowel obstruction or toxic megacolon in susceptible patients.
Not suitable for children younger than 6 years; use in under 13 years requires medical justification.
Alcohol and other CNS depressants may potentiate sedative effects and respiratory depression.
Overdose may result in life-threatening symptoms requiring immediate medical intervention.
Symptoms of overdose include weakness, blurred vision, slurred speech, seizures, and coma.
May cause dehydration if diarrhea persists; monitor fluid and electrolyte status carefully.
Use cautiously in patients with Down's syndrome due to potential for unusual responses.
Adverse cardiac effects such as tachycardia may occur, requiring careful cardiovascular monitoring.
Long term or excessive use may lead to drug dependence or withdrawal symptoms upon cessation.

Contraindication

Known hypersensitivity or allergy to diphenoxylate or atropine.
Diarrhea caused by bacterial infections such as Clostridium difficile or other invasive pathogens.
Patients with obstructive jaundice or severe liver disease.
Children below 6 years of age due to safety profile and risk of severe side effects.
Patients with acute dysentery characterized by blood in stools and high fever.
Those with abdominal pain of unknown origin without diarrhea confirmation.
Use during antibiotic-associated diarrhea where suppression of normal gut flora is contraindicated.
Patients with toxic megacolon or significant inflammatory bowel disease flare-ups.
Known or suspected paralytic ileus or severe gastrointestinal obstruction.
Concomitant use with monoamine oxidase inhibitors (MAOIs) due to potential interactions.
Situations where slowing gastrointestinal motility is harmful, such as certain infections.

Drug Interactions

Concurrent use with CNS depressants (e.g., opioids, benzodiazepines, alcohol) may enhance sedation and respiratory depression.
Co-administration with monoamine oxidase inhibitors (MAOIs) can potentiate anticholinergic and hypertensive effects.
Drugs that affect gastrointestinal motility may alter the absorption or efficacy of Lomotil.
Interaction with anticholinergic drugs can increase the risk of additive anticholinergic side effects.
Use with bronchodilators requires caution as atropine may increase heart rate and nervousness.
May reduce the effectiveness of antidiabetic medications through altered gastrointestinal transit.
Diphenoxylate metabolism may be affected by inhibitors or inducers of hepatic cytochrome P450 enzymes.
Concomitant use with bladder or urinary tract medications can exacerbate urinary retention.
Avoid use with medications that prolong QT interval or cause cardiac arrhythmias due to atropine effects.
Drugs causing electrolyte imbalances (like diuretics) may increase risk of toxicity with Lomotil.
Combination with muscle relaxants or anxiety medications may enhance CNS depression.
Interactions with proton pump inhibitors or antacids may affect drug bioavailability.
Herbal supplements with anticholinergic properties (e.g., jimsonweed) increase risk of adverse reactions.
Patients using rifampin or other potent enzyme inducers may experience reduced diphenoxylate efficacy.
Warfarin or other anticoagulants may have altered metabolism or increased bleeding risk when used concomitantly.

Preparations Of The Drug

Tablet: Each tablet contains diphenoxylate hydrochloride 2.5 mg and atropine sulfate 0.025 mg.
Oral solution: Each 5 mL contains diphenoxylate hydrochloride 2.5 mg and atropine sulfate 0.025 mg.
Combination formulations designed to discourage abuse by including subtherapeutic atropine doses.
Available in standard prescription strengths suitable for adult and adolescent dosing.
Manufactured for oral administration with standard excipients ensuring stability and bioavailability.
Provided with calibration devices such as dosing syringes for accurate liquid dosing.
Packaged in child-resistant containers to minimize accidental ingestion risks.
Formulations comply with regulatory standards for stability under room temperature storage.
Lomotil is manufactured as branded and generic formulations accessible in various healthcare settings.
Available in blister packs or bottle forms with clearly labeled dosing instructions.
Prescription-only product requiring healthcare provider oversight for use and dosage adjustments.
May be combined with electrolyte solutions for comprehensive diarrhea management.
Formulations designed to minimize central opioid effects while maximizing peripheral antidiarrheal action.
Produced under quality control systems ensuring consistency of active ingredient concentrations.
Supply includes comprehensive patient information leaflets to guide safe and effective use.